Rdcthera Announces RDC Development and Analysis Services Based on Its Technology Platform
In a groundbreaking development for the field of drug discovery and diagnosis, Rdcthera, a professional CRO company offering efficient and customized R&D services related to radionuclide drug conjugates (RDCs), has announced the release of its RDC development and analysis services. Leveraging its cutting-edge technology platform, Rdcthera aims to empower drug developers with state-of-the-art tools for creating targeted radiopharmaceutical treatments.
View full press release